Last reviewed · How we verify
HES 6%
At a glance
| Generic name | HES 6% |
|---|---|
| Sponsor | B. Braun Melsungen AG |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection (NA)
- Cardiac Output in Preeclamptic (NA)
- Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (PHASE2)
- A Dose-Image Optimization Trial Evaluating Mannitol and Voluven as Adjuncts for Indocyanine Green (PHASE1, PHASE2)
- Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence (NA)
- Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery (PHASE4)
- The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HES 6% CI brief — competitive landscape report
- HES 6% updates RSS · CI watch RSS
- B. Braun Melsungen AG portfolio CI